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effects of apelin on ALP activity/expression and Runx2, but 
PD98059 and LY294002 abolished the effect. These results 
demonstrate that apelin attenuates the osteoblastic differentia-
tion of AVICs via the ERK and PI3-K/Akt pathway.
Keywords Aortic valve calcification · APJ · Alkaline 
phosphatase · Runt-related transcription factor 2 · 
Mineralization
Abbreviations
ALP  Alkaline phosphatase
AVC  Aortic valve calcification
AVICs  Aortic valve interstitial cells
AS  Aortic valve stenosis
BCIP/NBT  4-Chloro-3-indolyl phosphate/nitroblue  
tetrazolium chloride
CAVD  Calcific aortic valve diseases
CAVICs  Calcific human AVICs
Runx2  Runt-related transcription factor 2
DXM  Dexamethasone
ERK  Extracellular signal-regulated kinase
β-GP  Beta-glycerophosphate disodium
MAPK  Mitogen-activated protein kinase
PBS  Phosphate buffer saline
PCM  Pro-calcific medium
PI3-K  Phosphatidylinositol 3-kinase
VHD  Valvular heart diseases
Vit C  Ascorbic acid
VSMCs  Vascular smooth muscle cells
Introduction
Aortic valve stenosis (AS) is the most frequent type of val-
vular heart diseases (VHD) in Europe and North America, 
Abstract Aortic valve calcification (AVC), which used to 
be recognized as a passive and irreversible process, is now 
widely accepted as an active and regulated process character-
ized by osteoblastic differentiation of aortic valve interstitial 
cells (AVICs). Apelin, the endogenous ligand for G-protein-
coupled receptor APJ, was found to have protective cardio-
vascular effects in several studies. However, the effects and 
mechanisms of apelin on osteoblastic differentiation of AVICs 
have not been elucidated. Using a pro-calcific medium, we 
devised a method to produce calcific human AVICs. These 
cells were used to study the relationship between apelin and 
the osteoblastic calcification of AVICs and the involved sign-
aling pathways. Alkaline phosphatase (ALP) activity/expres-
sion and runt-related transcription factor 2 (Runx2) expres-
sion were examined as hallmark proteins in this research. The 
involved signaling pathways were studied using the extracellu-
lar signal-regulated kinase (ERK) inhibitor, PD98059, and the 
phosphatidylinositol 3-kinase (PI3-K) inhibitor, LY294002. 
The results indicate that apelin attenuates the expression and 
activity of ALP, the expression of Runx2, and the formation of 
mineralized nodules. This protective effect was dependent on 
the dose of apelin, reaching the maximum at 100 pM, and was 
connected to activity of ERK and Akt (a downstream effec-
tor of PI3-K). The activation of ERK and PI3-K initiated the 
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and calcific AS is the primary presentation in adults of 
advanced age (2–7 % of the population >65 years of age) 
(Vahanian et al. 2012; Iung et al. 2003; Nkomo et al. 2006). 
Calcific aortic valve diseases (CAVD) are characterized by 
the deposition of calcified plaques, thickening and rigidity 
of the leaflets, and are increasingly affecting the aged popu-
lation. Many factors contribute to the risk of the disease, 
including age, sex, tobacco use, hypercholesterolemia, and 
hypertension, all having worldwide distribution (Rajaman-
nan et al. 2011).
Aortic valve calcification (AVC) used to be described as 
degenerative and irreversible (Sell and Scully 1965). Cur-
rently, surgery is the only effective option for patients with 
calcific AS, since the mechanisms of valve calcification 
are poorly understood and the non-surgical options are not 
defined. However, many recent studies suggest AVC is not 
a passive, degenerative, irreversible aortic valve disease, 
but the result of an active, regulated and reversible pro-
gression in the pathogenesis of calcification, including the 
osteoblastic differentiation of aortic valve interstitial cells 
(AVICs) and resulting osteogenesis (Mohler et al. 2001; 
Rajamannan et al. 2003). We have provided evidence that 
AVC resembles osteogenesis, and that AVICs play a crucial 
role in this process (Feng et al. 2012). The osteoblastic dif-
ferentiation of AVICs is the core mechanism ofAVC. As we 
described previously, AVICs function both as fibroblasts, 
secreting collagen and shaping the extracellular matrix, and 
as smooth muscle cells contracting according to the tension 
of the aortic valve. In pro-calcific medium (PCM) contain-
ing dexamethasone, AVICs differentiate into osteoblasts 
capable of calcium deposition and express markers of oste-
oblast formation runt-related transcription factor 2 (Runx2) 
and alkaline phosphatase (ALP).
Apelin, a 77 amino acid pre-pro-peptide, was first dis-
covered by activating the G-protein-coupled receptor APJ 
(Tatemoto et al. 1998). Apelin can be cleaved into active 
fragments of various sizes. The major active forms have 13 
to 36 residues, such as apelin-13. APJ, the apelin receptor, 
was first described as a receptor resembling AT1, angioten-
sin-I receptor (O’Dowd et al. 1993), and is a member of the 
rhodopsin family (Fredriksson et al. 2003) of heptahelical 
G-protein-coupling receptors, also known as family A of 
these receptors (Horn et al. 1998). APJ is widely distributed 
in the cardiovascular system, myocardial cells, endothelial 
cells, and vascular smooth muscle cells (VSMCs) (Hosoya 
et al. 2000; Kawamata et al. 2001; Kleinz and Davenport 
2004; Kleinz et al. 2005).
In recent years, the apelin/APJ pathway was demon-
strated as a potent regulator of cardiovascular function, 
mediating adaptation to physiological stress and disease 
(Lee et al. 2006; Quertermous 2007; Chandrasekaran 
et al. 2008; Peltonen et al. 2009; Shan et al. 2011; Cui 
et al. 2010), including contractility in cardiomyocytes, 
proliferation and myosin light chain phosphorylation in 
VSMCs, and inhibition of calcification and apoptosis 
of VSMCs. This encouraged us to investigate how ape-
lin/APJ act in AVC. Apelin was found to be expressed in 
aortic valvular endothelial cells, with lower expression in 
calcific valves, where the apelin-APJ signaling pathway 
was found to be significantly up-regulated (Peltonen et al. 
2009). However, the exact mechanism of apelin in AVC, 
and specifically which occurs in AVICs, has not yet been 
elucidated.
The present study is based on hypothesis that the apelin/
APJ signaling system is involved in the osteoblastic differ-
entiation of human AVICs. To explore the effect of apelin 
on the osteoblastic differentiation of human AVICs and 
the potential mechanisms, we induced calcification of cul-
tured using pro-calcific medium containing dexamethasone 
(DXM), and examined the potential cell signaling pathways 
involved in osteoblastic calcification as related to treatment 
with apelin. The results show that apelin can directly regu-
late the osteoblastic differentiation of human AVICs via the 
extracellular signal-regulated kinase (ERK) and phosphati-
dylinositol 3-kinase (PI3-K)/Akt signaling pathways. This 
new evidence provides a novel preventive and therapeutic 
strategy for AVC.
Materials and methods
Isolation and culture of cells
The aortic valves were collected by Bentall surgery at the 
Second Xiangya Hospital of Central South University, from 
patients having the Stanford type A aortic dissection. The 
patients (mean age 30 ± 7.5 years) had no previous heart 
valvular diseases. The tiny lesions of aortic valvular leaflets 
were removed during the pathological examination. This 
study was approved by the ethics committee of the Sec-
ond Xiangya Hospital, and all patients provided informed 
consent.
The isolation and culture of AVICs was performed as 
previously described (Feng et al. 2012; Meng et al. 2008), 
with some modifications. The distal 2/3 of the aortic valve 
leaflets were collected in the operating room and rinsed in 
phosphate buffer saline (PBS) with penicillin G/streptomy-
cin (200 U/ml). The leaflets were finely minced (1 × 1 mm) 
and then digested with 2.5 mg/ml type II collagenase and 
0.125 % trypsin with 0.02 % EDTA for 90 min at 37 °C, 
with vortexing for 10 s every 15 min. The softened leaflet 
fragments with free cells were centrifuged at 1000 g for 
5 min. Then, the supernatant was discarded and the pre-
cipitate was blended in full medium [Dulbecco’s Modified 
Eagle’s Medium (DMEM, Hyclone with 4.5 g/L glucose) 
with 20 % fetal bovine serum (Hyclone) and penicillin 
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G/streptomycin)]. Finally, cells were plated onto six-well 
plates and cultured in a cell culture incubator supplied with 
5 % CO2. Upon reaching 80–90 % confluence, the cells 
were sub-cultured in 75 cm2 flasks, and passages 3–6 were 
used for experiments. To ensure that the cultured cells were 
not contaminated with other cells throughout the process, 
we had detected SM α-actin, vimentin, SM-myosin, desmin 
and CD31 by immunohistochemical method as described 
in our previous study (Feng et al. 2012).
Expression of APJ in cultured human AVICs
To check for expression of APJ in human AVICs, west-
ern blotting and immunohistochemical method were per-
formed. The cells cultured in a 48-well plate were washed 
with PBS, and fixed in 4 % paraformaldehyde for 5 min. 
Cells were blocked by non-immune goat serum and incu-
bated with antihuman APJ (Proteintech) overnight at 4 °C. 
The cells were then washed with PBS and incubated with 
goat anti-rabbit antibody conjugated with biotin (Beyo-
time) for 20 min at room temperature. Following that, the 
cells were washed by PBS and incubated with streptavidin-
conjugate horseradish peroxidase. Cells were then stained 
by the AEC method. Stained cells were visualized using a 
Nikon TE300 phase contrast microscope.
Alkaline phosphatase activity
The AVICs at about 90 % confluence in 48-well plates were 
divided into six groups. These groups were treated with 
full medium, PCM [containing 10 mM beta-glycerophos-
phate disodium (β-GP), 10 nM dexamethasone (DXM) and 
50 μg/ml ascorbic acid (Vit C)], and PCM with four dif-
ferent concentrations of apelin every other day. The first 
day of culture in the supplement was defined as day 0. On 
day 21 of the experiment, ALP activity was detected by the 
4-chloro-3-indolyl phosphate/nitroblue tetrazolium chlo-
ride (BCIP/NBT) method.
Osteoblastic differentiation of cells
The AVICs at about 90 % confluence in 24-well plates 
were divided into three groups, which were, respectively, 
treated with full medium, PCM and PCM with 100 pM 
apelin every other day. The first day of culture in PCM was 
defined as day 0. The calcification of cells was detected 
on day 21 by von Kossa staining. Then, quantification of 
calcium content in calcified plaques was performed as pre-
viously described (Feng et al. 2012). The three groups of 
cells were decalcified with 0.6 M HCL for 24 h. The cal-
cium content was determined by measuring the concentra-
tions of calcium in the supernatant by atomic absorption 
spectroscopy. The remaining cells were washed with PBS 
for three times and lysed in 1 × cell lysis buffer with com-
plete EDTA-free protease inhibitor. The total protein con-
tent was measured by the BCA method, and the calcium 
content was normalized to total protein content.
Western blotting
AVICs in 6-well plates were lysed in 1 × cell lysis buffer 
(Beyotime) with complete EDTA-free protease inhibitor 
(Roche). The protein content was detected using the bicin-
choninic acid (BCA) method. Denatured protein samples 
with 1 × loading buffer were separated by 12 % poly-
acrylamide gel electrophoresis followed by transfer to a 
pure nitrocellulose blotting membrane (Pall Corporation). 
Proteins of interest (such as APJ, ALP, Runx2) were then 
blotted using antihuman antibodies (Proteintech), horserad-
ish peroxidase conjugate second antibody (Proteintech) and 
Western blot chemiluminescence detection (Millipore). The 
expression of target protein was normalized to β-actin.
Detection of mitogen‑activated protein kinase (MAPK) 
and PI3‑K/Akt
Cultured cells in 6-well plates were first treated with 
100 pM apelin for 0, 5, 15, 30, 60 or 120 min. The treated 
cells were also lysed in 1 × cell lysis buffer (Beyotime) 
with complete EDTA-free protease inhibitor (Roche). The 
BCA method was used to determine the protein content. 
Western blotting was performed as above. Proteins were 
then transferred to a nitrocellulose membrane. The mem-
brane was incubated with ERK, phosphate-ERK, p38, 
phosphate-p38, c-Jun N-terminal kinases (JNK), phos-
phate-JNK, Akt, or phosphate-Akt antibodies (Santa Cruz) 
at 1:1000 dilution overnight. The membrane was then incu-
bated with goat anti-mouse IgG antibody or rabbit IgG/
horseradish peroxidase conjugate at 1:5000 in PBS for 
1 h. Blots were processed using an ECL kit and exposed to 
X-ray film.
Data presentation and statistics
All data are presented as mean ± standard error. Compari-
sons among values of more than two groups were performed 
by one-way ANOVA. A P value below 0.05 was considered 
significant.
Results
Human AVICs express APJ
Using immunohistochemistry, we found that human AVICs 
expressed APJ. To further confirm the result, western 
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APJ     
β-actin




Fig. 1  The expression of APJ in AVICs. Staining of cultured AVICs. a Negative control incubated with PBS, b APJ positive incubated with anti-
APJ. c Western blotting shows APJ positive incubated with anti-APJ
Control PCM 10 pM 100 pM 1 nM 10 nM
B
A
Fig. 2  The effect of apelin on ALP activity. Human AVICs were 
induced with PCM containing apelin at different concentrations for 
14 days. a A representative view of the BCIP/NBT staining method 
in 48-well plates. b A representative microscopic view of the BCIP/
NBT method staining at a magnification of ×400 in 48-well plates
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blotting was also performed. As seen in Fig. 1b, and the last 
two lanes in Fig. 1c, APJ expression was positive. The PBS 
negative control is shown in Fig. 1a and the first two lanes 
in Fig. 1c.
Apelin attenuates osteoblastic differentiation 
and mineralization of human AVICs
Calcific aortic valve expresses some bone-related mole-
cules, such as osteopontin (OPN), osteoprotegerin (OPG), 
ALP, and Runx2, and the valve calcification process resem-
bles the bone mineralization process (Mohler et al. 2001). 
To identify the effect of apelin on the osteoblastic differ-
entiation and mineralization of human AVICs, we supple-
mented the cells in PCM with apelin at different concen-
trations, and examined two important osteoblastic markers, 
ALP and Runx2, as well as mineralization.
After stimulating the cells for 14 and 21 days, ALP 
expression and cell mineralization were strongest (Figs. 2, 
3, 4). Figures 2 and 3 show cells treated with normal 
medium, PCM, and PCM with apelin at 10 pM, 100 pM, 
1 nM and 10 nM every other day. In comparison with 
the blank control and the PCM groups, western blotting 
showed that apelin decreased the ALP activity and expres-
sion dramatically in a dose-dependent manner (Figs. 2a, 
b, 3) (*P < 0.05 vs. PCM), especially at the concentra-
tion of 100 pM. However, this effect was suppressed by 
PD98059 and LY29402 (#P < 0.05 vs. PCM + 100 pM 
apelin). Figure 4 shows the result for cells treated with 
normal medium, PCM and PCM with 100 pM apelin for 
21 days every other day. The cell calcification was most 
obvious in the PCM group, and it was significantly attenu-
ated by apelin in the form of calcium content (*P < 0.05 
vs. PCM).
Similarly, we stimulated cells with the above supple-
ment for 24 h, and Runx2 expression was examined. In 
Fig. 5, the changes in Runx2 expression were consistent 
with ALP and mineralization, and the apparent decrease 
occurred at 100 pM apelin. Western blotting showed 
that apelin dramatically decreased Runx2 expression in 
a dose-dependent manner (*P < 0.05 vs. PCM), espe-
cially at 100 pM (*P < 0.05 vs. PCM + other concen-
tration groups of apelin). This effect was suppressed by 
PD98059 and LY29402 (#P < 0.05 vs. PCM + 100 pM 
apelin).
PCM ( - ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + )
Apelin 0 0 10-11  10-10 10-9 10-8 10-10 10-10 M
PD98059 0 0 0 0 0 0 10 0 µM
LY29402 0 0 0 0 0 0 0 10 µM
ALP   
β-actin 
Fig. 3  The effect of apelin on ALP expression. Human AVICs were 
induced with PCM containing apelin at different concentrations (0, 
10 pM, 100 pM, 1 nM and 10 nM) as well as PD98059 (ERK inhibi-
tor) and LY29402 (Akt inhibitor) for 14 days
Fig. 4  The effect of apelin on AVIC mineralization. Human AVICs 
were incubated in vehicle, PCM and PCM containing 100 pM ape-
lin for 21 days. a A representative entire plate view of the von Kossa 
staining method in 24-well plates. b A representative microscopic 
view of von Kossa method staining at a magnification of ×400 in 
24-well plates. c Calcium content was reduced by apelin (*P < 0.05 
vs. PCM group)
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Apelin activates the ERK and PI3‑K/Akt pathways 
in human AVICs
In our previous work, mitogen-activated protein kinase 
(MAPK) and PI3-K/Akt were found to play essential 
roles in regulating cell differentiation and it was deter-
mined that apelin regulates osteoblastic differentiation 
through the ERK and PI3-K/Akt pathways (Shan et al. 
2011). Hence, we examined the level of MAPK and 
PI3-K/Akt signaling, induced by apelin (100 pM) with 
PCM in human AVICs, at 0, 5, 15, 30, 60 and 120 min 
(Fig. 6). Phosphorylated c-Jun N-terminal kinases 
(p-JNK) and phosphorylated p38 MAP kinases were 
not detected at any time; however, phosphorylated ERK 
(p-ERK) and phosphorylated Akt (p-Akt) increased dra-
matically after 5 min of incubation. This result indicates 
that ERK and PI3-K/Akt can be activated by apelin. This 
was further confirmed by treating the cells with PD98059 
(ERK inhibitor) and LY294002 (PI3-K/Akt inhibitor). As 
shown in Figs. 3 and 5, ALP and Runx2 expression did 
not decrease.
Discussion
Ectopic calcification of the cardiovascular system pre-
dominantly affects the aorta, coronary arteries and periph-
eral arteries. Traditionally, cardiovascular calcification 
has been considered to be passive phenomenon associated 
with aging. However, it is currently viewed as an actively 
regulated disease process, and increasing evidence sug-
gests that the underlying mechanisms of cardiovascular 
calcification are similar to embryonic bone formation 
(Demer and Tintut 2008; Otto 2008; Towler and Demer 
2011). AVC is considered as similar to osteogenesis. 
AVICs may undergo a phenotype transition to become 
osteoblast-like cells and elaborate bone matrix (Leopold 
2012; Rajamannan et al. 2003). AVICs are the predomi-
nant cells in the aortic valve, and aortic valve disease is 
usually related to AVICs lesions. Therefore, the transi-
tion process of AVICs to osteogenic phenotype may play 
a central role in AVC. The process is similar to that in 
VSMCs during arterial calcification (Feng et al. 2012; 
Liao et al. 2008).
The transition of AVICs to an osteogenic phenotype 
usually occurs in a specific pro-calcific matrix (PCM). 
β-GP is the major pro-calcific component, and DXM and 
ascorbic acid should also be supportive. We have success-
fully established a model of AVICs calcification in vitro 
(Feng et al. 2012). The present study further supports 
the cell culture calcification model. Of the two chosen 
PCM  ( - ) ( + )  ( + ) ( + ) ( + )  ( + ) ( + ) ( + )
Apelin  0   0    10-11 10-10 10-9 10-8 10-10 10-10 M
PD98059 0   0    0    0   0   0  10 0  µM
LY294002 0   0    0    0   0    0   0    10  µM
Runx2
β-actin
Fig. 5  The effect of apelin on Runx2 expression. Human AVICs 
were induced by PCM with apelin of different concentrations (0, 
10 pM, 100 pM, 1 nM and 10 nM) as well as PD98059 (ERK inhibi-









0 5 15 30 60 120 min
Fig. 6  The effect of apelin on MAKP and PI3-K/Akt activation in 
the osteoblastic differentiation of human AVICs. AVICs were incu-
bated with 100 pM apelin in PCM for 0, 5, 15, 30, 60 or 120 min 
after incubation in serum-free medium for 5 h. Cell lysates were 
subjected to western blotting and incubated with antibodies against 
p-ERK, t-ERK, p-Akt, t-Akt, p-JNK, t-JNK, p-P38, and t-P38. 
The results show that exposure of the cells to 100 pM apelin for 
5–120 min activated the ERK and Akt signaling pathways
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markers, ALP is an early marker of osteoblastic differ-
entiation and Runx2 is the nuclear transcription factor of 
osteoblastic differentiation which binds to the osteoblast-
specific cis-acting element OSE2 (Liao et al. 2013; Liu 
et al. 2014).
Apelin is an adipokine that distributes primarily in 
the endothelium and activates APJ via both pericellular 
and endocrine signaling pathways. In the cardiovascu-
lar system, APJ is expressed widely by myocardial cells, 
endothelium and VSMCs. Increasing evidences have dem-
onstrated that the apelin/APJ system plays a critical role in 
regulating cardiovascular function and in mediating adap-
tation to physiological stress and diseases. This system is 
involved in lowering arterial blood pressure, endothelium-
intact mammary artery vasodilatation, facilitating neovas-
cularization in the peri-infarct myocardium, decreasing 
systemic venous tone, reducing left ventricular preload 
and afterload without cardiac hypertrophy, promoting dier-
esis and contractility in cardiomyocytes (Farkasfalvi et al. 
2007). Moreover, apelin/APJ has been found to correlate 
with many cardiovascular diseases, such as atherosclero-
sis, coronary heart disease, heart failure, hypertension, 
pulmonary artery hypertension, myocardial ischemia–
reperfusion injury and atrial fibrillation (Yu et al. 2014). 
Recently, the apelin/APJ signaling pathway was found to 
be significantly up-regulated in calcific aortic valves, but 
the exact ectopic calcific mechanism was not elucidated 
(Peltonen et al. 2009). However, some studies have shown 
that apelin/APJ can suppress osteoblastic differentiation 
of VSMCs via the ERK and PI3-K signaling pathways 
in vitro (Shan et al. 2011).
The present research demonstrates that apelin/APJ 
inhibits the osteoblastic differentiation of AVICs in a dose-
dependent manner in cell culture. Interestingly, the optimal 
protective effect occurs at the concentration of 100 pM ape-
lin other than 1 or 10 nM. This phenomenon is consistent 
with the result of apelin inhibiting osteoblastic differenti-
ation of vascular smooth muscle cells (Shan et al. 2011), 
which showed that effect of apelin occurred dramatically at 
1 nM other than 10 nM. Given these findings, we conclude 
that apelin plays a widely part in variety of tissues calcifi-
cation, and the effect of apelin would take the concentra-
tion into account. The mechanism involves activation of the 
APJ/ERK and APJ/PI3-K/Akt signaling pathways. Apelin 
appears to have a protective role in AVC and it is possible 
that treatment with apelin could be helpful in prevention of 
AVC.
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